Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1

Philip M. Bauer1,2†, Eileen M. Bauer2†, Natasha M. Rogers2, Mingyi Yao2, Monica Feijoo-Cuaresma3, Joseph M. Pilewski4, Hunter C. Champion2,4, Brian S. Zuckerbraun1, Maria J. Calzada3, and Jeffrey S. Isenberg2,4*

1Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 3Immunology Service, Instituto de Investigacion Princesa, Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain; and 4Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

Received 14 October 2011; revised 12 December 2011; accepted 22 December 2011; online publish-ahead-of-print 2 January 2012

Aims
Pulmonary arterial hypertension (PAH) is a progressive lung disease characterized by pulmonary vasoconstriction and vascular remodelling, leading to increased pulmonary vascular resistance and right heart failure. Loss of nitric oxide (NO) signalling and increased endothelial nitric oxide synthase (eNOS)-derived oxidative stress are central to the pathogenesis of PAH, yet the mechanisms involved remain incompletely determined. In this study, we investigated the role activated CD47 plays in promoting PAH.

Methods and results
We report high-level expression of thrombospondin-1 (TSP1) and CD47 in the lungs of human subjects with PAH and increased expression of TSP1 and activated CD47 in experimental models of PAH, a finding matched in hypoxic human and murine pulmonary endothelial cells. In pulmonary endothelial cells CD47 constitutively associates with caveolin-1 (Cav-1). Conversely, in hypoxic animals and cell cultures activation of CD47 by TSP1 disrupts this constitutive interaction, promoting eNOS-dependent superoxide production, oxidative stress, and PAH. Hypoxic TSP1 null mice developed less right ventricular pressure and hypertrophy and markedly less arteriole muscularization compared with wild-type animals. Further, therapeutic blockade of CD47 activation in hypoxic pulmonary artery endothelial cells upregulated Cav-1, increased Cav-1CD47 co-association, decreased eNOS-derived superoxide, and protected animals from developing PAH.

Conclusion
Activated CD47 is upregulated in experimental and human PAH and promotes disease by limiting Cav-1 inhibition of dysregulated eNOS.

Keywords
Pulmonary arterial hypertension • CD47 • eNOS • Caveolin-1 • Reactive oxygen species

1. Introduction
Pulmonary arterial hypertension (PAH) is a disease of the small pulmonary arteries marked by a progressive increase in pulmonary vascular resistance, leading to uncompensated right heart failure and ultimately death.1–3 While idiopathic PAH (IPAH) occurs in the absence of any known insult, secondary PAH results from a number of pathological conditions.4–8 Independent of its aetiology PAH is characterized by remodelling of the pulmonary vasculature, vasoconstriction, and thrombosis in situ.1

One of the key initiating events leading to PAH is endothelial dysfunction characterized by uncoupling of endothelial nitric oxide synthase (eNOS) and an associated lack of bioavailable nitric oxide (NO).6–8 Not surprisingly, eNOS null mice are more susceptible to the development of PAH.9 Regulation of eNOS activity is complex and depends on phosphorylation, protein–protein interactions, and localization to specialized areas of the cell membrane.10,11 Caveolin-1 (Cav-1) limits eNOS activity via direct association.12,13 Dissociation or loss of Cav-1 leads to pathological eNOS hyperactivity,14 and Cav-1 null mice spontaneously develop pulmonary hypertension15–17 that
CD47 promotes pulmonary arterial hypertension

2. Methods

Detailed information on the materials and methods used in this study is provided in the Supplementary material online.

2.1 Animal studies

All studies were performed under a protocol approved by the University of Pittsburgh Institutional Animal Care and Use Committee (IACUC) or under a protocol approved by the Committee for Research and Ethics of the Universidad Autonoma de Madrid and in accordance with Directive 2010/63/EU of the European Parliament. Male C57BL/6 wild-type, TSP1, and CD47 null mice (stock numbers 000664, 006141, and 003173, respectively) were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). Male Sprague Dawley rats were obtained from Harlan (Indianapolis, IN, USA). Adequacy of anesthesia was monitored at all times by assessment of skeletal muscle tone, respiration rate and rhythm, and response to tail pinch. Euthanasia was achieved by isoflurane inhalational anesthesia (1.5%) and concurrent cervical dislocation (mice) or anaesthetic overdose (rats) as approved by the respective University IACUCs.

2.2 Human tissue studies

Use of human tissues was within ongoing IRB approved protocols at the University of Pittsburgh and Johns Hopkins University and conformed to the principles outlined in the Declaration of Helsinki.

2.3 Cell cultures

Primary murine pulmonary microvascular endothelial cells were harvested from 8- to 10-week-old male C57BL/6 wild-type and TSP1 null mice as previously published.26 Human pulmonary arterial and microvascular endothelial cells were purchased from Lonza (Switzerland).

is ameliorated by re-expression of Cav-1 in the endothelium18 or eNOS inhibition.19,20 Finally, in human studies, loss of pulmonary Cav-1 has been linked to PAH.21,22

Work by our group has found that the matricellular protein thrombospondin-1 (TSP1), through binding to its cognate receptor CD47, blocks physiological NO responses in vascular cells.23,24 Pulmonary vascular endothelial cells from TSP1 and CD47 null mice maintain elevated levels of the NO second messenger cyclic guanosine monophosphate (cGMP).25,26 Recent data also indicate that plasma TSP1 is a potent inhibitor of eNOS in endothelium and supresses endogenous NO production in the vasculature.27

We hypothesized that TSP1 and CD47 contribute to the development of PAH in humans. Interestingly, we observed a marked upregulation of TSP1 and CD47 protein and mRNA in patients with PAH. Findings of upregulation of the TSP1-CD47 axis in human PAH were paralleled by upregulation of both TSP1 and CD47 in experimental models of PAH. In pulmonary endothelial cells, CD47 constitutively associates with Cav-1. Conversely, in hypoxic animals and cell cultures, activation of CD47 by TSP1 disrupts this constitutive interaction, promoting eNOS-dependent superoxide production, oxidative stress, and PAH. Hypoxic TSP1 null mice developed less right ventricular pressure and hypertrophy and markedly less arteriolar muscularization and thickening compared with wild-type animals. Therapeutic blockade of CD47 activation in hypoxic pulmonary arterial endothelial cells upregulated Cav-1, increased Cav-1CD47 co-association, decreased eNOS-derived superoxide, and protected animals from developing PAH.

2.4 Murine chronic hypoxic exposure model of PAH

Nine- to 12-week-old male wild-type, TSP1 and CD47 null mice were placed in an airtight hypoxia chamber and exposed to acute (FiO₂ = 7.5%) or chronic (FiO₂ = 10%) hypoxia for the indicated time. Mice maintained in room air served as controls.

2.5 Haemodynamic and ventricular weight measurements

Animals were anaesthetized with pentobarbital (40 mg/kg ip). The trachea was cannulated, and animals were ventilated with 1.5% isoflurane. The thoracic cavity was opened, a Millar catheter was inserted into the right ventricle (RV), and RV systolic pressure was measured with PowerLab monitoring equipment. The ratio of RV weight to left ventricular (LV) weight plus septum (S) (RV/LV + S) was used as an index of RV hypertrophy (Fulton Index).

2.6 Murine lung histology

Mouse lungs were perfused with PBS, fixed with 4% paraformaldehyde under a standardized inflation pressure and excised (12 h PFA 4°C). Lungs were transferred into 30% sucrose (overnight, 4°C), paraffin embedded and sectioned (10 μm), and stained for α-smooth muscle actin. For pulmonary vascular morphometry studies, images of peripheral arterioles were captured with a Nikon Eclipse 800 microscope.

2.7 Rat monocrotaline model of PAH

As we have previously published, male Sprague Dawley rats were treated with monocrotaline (50 mg/kg)28 or monocrotaline and a CD47-blocking antibody (clone OX101, 1 μg/gram body weight) on day 1 and day 14. On day 28, animals were anaesthetized with pentobarbital (40 mg/kg ip) and 2% isoflurane and right RV pressure and Fulton index determined. Lung sections were stained with haematoxylin and eosin. Images for arterioles were captured with a microscope digital camera system (Prosvus, Olympus), and arterial area was measured using an image analysis programme.

2.8 Protein expression by western blot analysis

Lysates of lung tissues (human, murine, and rat) and human and murine pulmonary endothelial cells were subjected to western analysis. Protein was resolved by SDS–PAGE and transferred onto nitrocellulose. Blots were probed with primary antibody to the respective proteins and were visualized after 1 h incubation in secondary antibody on an Odyssey Imaging System (Licor).

2.9 Co-immunoprecipitation

Immunoprecipitation was performed as we have published with minor modification.37 Human pulmonary microvascular endothelial cells (passages 2–4) were serum starved over 24 h, incubated in basal medium without serum containing 0.1% BSA for 90 min and then treated with TSP1 ± hypoxia (1% O₂) for 4 h, lysate prepared and precipitated with a Cav-1 or a CD47 antibody. Protein was separated via gel electrophoresis and transferred to membranes and blotted against Cav-1 or CD47.

2.10 siRNA knockdown of Cav-1

All siRNAs were designed and synthesized by Dharmacon (ThermoFisher Scientific). siRNA transfection was performed using a lipofectamine reagent (Invitrogen) according to the manufacturer’s instructions. Gene silencing was established by western blot analysis 72 h after transfection.

2.11 Real-time quantitative PCR

Total RNA from murine and human samples was extracted using Qiagen RNeasy® Mini Kits (Qiagen). One microgram of RNA was
treated with DNase I (Invitrogen) and then reverse-transcribed. cDNA was amplified using Platinum® PCR SuperMix-UDG (Invitrogen). For details on primers and cycle conditions, see the supplementary material online.

2.12 Determination of monomer to dimer ratio eNOS protein

Tissue samples were prepared as described for western analysis with the following exceptions: samples of equal protein content were kept for 5 min at room temperature and one sample was boiled to serve as a control for monomer formation. Samples were then resolved on an 8% SDS–PAGE on ice, at 100 V and transferred and blotted against total eNOS.

2.13 Determination of nitrotyrosine formation in the lung

Lung sections were de-paraffinized, rehydrated, and microwaved in sodium citrate buffer (pH 6, 10 min) for antigen retrieval. Sections were blocked and stained with a rabbit nitrotyrosine antibody (rabbit anti-nitrotyrosine, Millipore, 1: 100, Cat. No. ab5411) in combination with a Vectastain ABC kit (Vector Laboratories) and a metal-enhanced DAB substrate kit (Thermo Scientific). Sections were counterstained for haematoxylin (Vector Laboratories), dehydrated, and covered.

2.14 Measurement of intracellular $O_2^−$

Human pulmonary artery endothelial cells (hPAEC) were grown to confluence and exposed to 1% O$_2$ or normoxia for 24 h. Dihydroethidium (DHE) was added for the final 30 min of the 24 h incubation period. O$_2^−$ was evaluated by measuring the conversion of DHE to hydroxyethidium in a fluorimeter.

2.15 Gain-of-function studies in pulmonary endothelial cells

Murine pulmonary endothelial cells were harvested from age-matched male wild-type and TSP1 null mice. Cells were plated at 80% confluence, treated with normoxia or hypoxia (1% O$_2$ ± exogenous TSP1 for 24 h), cell lysate prepared and western blot analysis performed.

2.16 Statistics

Statistics were performed using GraphPad Prism software (GraphPad Software, Inc., CA, USA). Data were analysed by one-way ANOVA followed by the Tukey test for multiple comparisons. For grouped analysis, data were analysed by two-way ANOVA followed by the Bonferroni post hoc test.

3. Results

3.1 TSP1 and its cognate receptor CD47 are increased in PAH

The role of TSP1 in clinical PAH is unknown. Figure 1A shows a representative western blot of lung specimens from a historical cohort of non-PAH patients, scleroderma-associated PAH patients (SCD), and patients with IPAH. Densitometry of western blots from the total cohort of 10 non-PAH patients, and 10 PAH patients (five SCD and five IPAH), reveals a significant increase in TSP1 protein expression in both SCD and IPAH compared with samples from patients without PAH ($P < 0.05$). Equally unknown is the role of CD47 in PAH. Western blot analysis of lung samples from a prospective cohort (three control and five PAH patients) demonstrated upregulation of pulmonary CD47 (Figure 1B) and TSP1 (data not shown) in PAH lungs compared with control lungs. Analysis of transcript demonstrated a significant fold increase in both TSP1 and CD47 mRNA in PAH samples (Figure 1C).

3.2 Activated CD47 and TSP1 are upregulated in hypoxic murine PAH

Chronic hypoxia is an established method of inducing experimental PAH$^{29}$ and has a role in disease pathogenesis in human subjects.$^{30–32}$
We wished to determine whether TSP1 and CD47 were also induced in experimental PAH. Chronically hypoxic wild-type mice demonstrated significantly increased pulmonary TSP1 expression compared with normoxic controls (Figure 1D). Wild-type mice exposed to acute hypoxia demonstrated rapid induction of pulmonary TSP1 expression within 1 h (Figure 1E) that was paralleled by increases in TSP1 mRNA in lungs from wild-type mice (Figure 1F). TSP1 null mice have only partial deletion of the thrombospondin-1 (THBS1) gene and residual TSP1 mRNA transcript can be detected on PCR, but functional protein is not detectable on western.33 TSP1 null mice did not show pulmonary expression of TSP1 protein under normoxia or hypoxia (Figure 1D). However, in TSP1, null mice acute hypoxia decreased pulmonary TSP1 mRNA transcript (Figure 1F). In wild-type murine pulmonary microvascular endothelial cells, hypoxia induced expression of CD47 (Figure 1G). Interestingly, in normoxic TSP1 null pulmonary endothelial cells, CD47 expression was significantly lower compared with wild-type cells with no increase under hypoxia (Figure 1G). Analysis of lungs from hypoxic wild-type mice also demonstrated rapid induction of pulmonary CD47 (Figure 1H).

### 3.3 Activation of CD47 by TSP1 promotes hypoxic PAH

In experimental PAH and human disease, increased pulmonary vascular resistance results in increased right ventricular (RV) pressure and secondary RV hypertrophy.34 Chronic hypoxia led to a significant rise in RV pressure with associated RV hypertrophy in wild-type mice. However, in the absence of activated CD47, as in the TSP1 null mice, chronic hypoxia resulted in significantly decreased RV pressure and RV hypertrophy compared with wild-type animals (Figure 2A and B).

A hallmark of PAH is vascular remodelling.7 Figure 2C shows representative images of pulmonary arterioles from each treatment group stained for α-smooth muscle actin (brown staining). In the absence of CD47 activation, hypoxic TSP1 null mice demonstrated significantly less wall thickening compared with lung sections from wild-type mice. Results obtained by immunohistology were confirmed by analysis of arteriole wall thickness. Sections of lungs from hypoxic TSP1 null mice demonstrated significantly less wall thickening compared with lung sections from hypoxic wild-type mice (Figure 2D).

### 3.4 Under hypoxia activated CD47 inhibits upregulation of Cav-1

Next, we tested if activated CD47 promotes PAH through the inhibition of eNOS. Hypoxic wild-type and TSP1 null mice demonstrated increased pulmonary eNOS protein expression (Figure 3A and B). Maximal eNOS activity is associated with phosphorylation of eNOS at serine1176 in mice.35 Hypoxic wild-type mice showed no change in the ratio of phospho-eNOS to total eNOS compared with wild-type normoxic mice (Figure 3A and C). Normoxic TSP1 null mice demonstrated increased pulmonary eNOS phosphorylation of...
Activated CD47 regulates hypoxic eNOS by altering Cav-1/CD47 co-association. (A) Western blot of lung tissue from wild-type and TSP1 null mice exposed to chronic hypoxia or room air probed against total eNOS protein, eNOS phosphorylation at serine-1176 (murine residue), Cav-1, and β-actin. Quantification of densitometric analysis of the ratio of (B) total eNOS to β-actin, (C) p-eNOS to total eNOS, (D) Cav-1 to β-actin. Asterisk (*) indicates statistically significant difference (P < 0.05) compared with wild-type normoxic. Hash (#) indicates statistically significant difference (P < 0.05) compared with wild-type normoxic. All ratios represent mean ± SD and are the result of the total cohort (n = 8 animals per group). 

(E) Co-immunoprecipitation in human pulmonary microvascular endothelial cells of Cav-1 and CD47. Immunoprecipitation was with monoclonal antibodies to Cav-1, CD47, or an isotype-matched control IgG antibody. Results presented are representative of four separate experiments. 

(F) Human pulmonary microvascular endothelial cells were serum starved and then treated with TSP1 (2.2 nmol/L) ± hypoxia (1% O2 for 4 h), lysate prepared and immunoprecipitation for CD47 performed with protein blotted for Cav-1. Results are presented as the quantification of densitometric analysis from three separate experiments of the ratio of Cav-1 to CD47 following immunoprecipitation. Asterisk (*) indicates statistically significant difference (P < 0.05) compared with normoxia. 

(G) Western blot of pulmonary Cav-1 from lung lysate from chronically hypoxic (21 days normobaric 10% O2) wild-type (n = 3) and CD47 null (n = 4) mice. Asterisk (*) indicates statistically significant difference (P < 0.05) compared with wild-type.
serine \(^{11,16}\) (Figure 3A and C). However, hypoxic TSP1 null mice displayed a decrease in pulmonary eNOS activity (phosphorylation) compared with normoxic null mice (Figure 3A and C) indicating that under hypoxia, CD47 does not directly inhibit eNOS activation.

These results raised the possibility that CD47 promotes PAH through alternative mechanisms. We examined Cav-1 expression in our hypoxic mice. Interestingly, in the lungs of hypoxic TSP1 null mice, and therefore absent activated CD47, Cav-1 was significantly upregulated (Figure 3A and D). By contrast, in the lungs of hypoxic wild-type mice, and therefore with activated CD47, no upregulation of Cav-1 was observed.

### 3.5 Cav-1 and CD47 co-associate on pulmonary endothelial cells and both TSP1 and hypoxia decrease this interaction

To account for the increased pulmonary Cav-1 in TSP1 null mice, we hypothesized that CD47 may interact with Cav-1. In lysates from human pulmonary microvascular endothelial cells, Cav-1 was co-precipitated by a CD47 monoclonal antibody and, conversely, CD47 was co-precipitated by a Cav-1 monoclonal antibody (Figure 3E). An isotype-matched control IgG antibody did not co-precipitate Cav-1 (Figure 3E) or CD47 (data not shown). Treating normoxic pulmonary endothelial cells with TSP1 decreased Cav-1-CD47 association (Figure 3F). Hypoxia, through upregulation of TSP1 (see Figure 5), decreased Cav-1CD47 association and exogenous TSP1 did not decrease this further (Figure 3F). Finally, lung samples from hypoxic CD47 null mice demonstrated increased Cav-1 expression compared with hypoxic wild-type animals (Figure 3G).

### 3.6 Activated CD47 promotes ROS in experimental PAH

PAH in Cav-1 null mice is mediated through overactive uncoupled eNOS and eNOS-derived reactive oxygen species (ROS). \(^{15-17}\) This suggested upregulation of Cav-1 in hypoxic TSP1 null mice may be a protective mechanism to suppress ROS production from dysregulated eNOS. To test if eNOS is dysregulated in our murine model of PAH, we determined eNOS monomer to dimer ratio (an established marker of eNOS enzymatic uncoupling and dysregulation) \(^{36,37}\) in pulmonary samples from hypoxic mice. Hypoxic wild-type and TSP1 null lungs showed a comparable increase in eNOS monomer to dimer ratio (Figure 4A and B).

We predicted that because pathological eNOS uncoupling occurred to an equal degree in lungs from both hypoxic wild-type and TSP1 null mice that this would result in comparable amounts of eNOS-derived ROS, oxidative stress, and protein nitration in both groups. Immunostaining of lung sections revealed increased nitrotyrosine staining in the samples from hypoxic wild-type mice. Surprisingly, hypoxic TSP1 null mice that lack activated CD47 demonstrated minimal nitrotyrosine staining of lung tissues (Figure 4C).

### 3.7 Activated CD47 promotes hypoxia-mediated ROS by inhibiting Cav-1

We next determined whether hypoxia-induced ROS production in hPAEC was associated with upregulation of TSP1. Exposure of hPAEC to hypoxia resulted in increased TSP1 expression (Figure 5A and B). This correlated with increased production of superoxide (Figure 5D) that was completely abrogated by the eNOS inhibitor L-NAME (Figure 5D), identifying uncoupled eNOS activity as the source of the ROS. To determine whether the increased eNOS-derived superoxide occurred via activation of CD47, we treated hPAEC with a CD47 activation blocking antibody. \(^{38}\) Treating hPAEC with the CD47 antibody inhibited hypoxia-induced superoxide production (Figure 5D), while increasing Cav-1 expression (Figure 5A and C).

To provide further proof that Cav-1 plays a role in ROS production by activated CD47, we used siRNA to knockdown Cav-1. Treatment of hPAEC with Cav-1 siRNA resulted in \(~90\%\) decrease in Cav-1 expression (Figure 5E). Exposure of control siRNA-treated cells to hypoxia had no effect on superoxide production or the ability of the CD47-blocking antibody to inhibit superoxide production (Figure 5F). However, knockdown of Cav-1 resulted in an increase
CD47 promotes pulmonary arterial hypertension
in hypoxia-induced superoxide and abolished the ability of the CD47 antibody to inhibit superoxide production. In gain-of-function experiments treating murine wild-type pulmonary microvascular endothelial cells with TSP1 to activate CD47 inhibited Cav-1 expression in a dose-dependent manner (Figure 5G), as did hypoxia. Conversely, Cav-1 was significantly upregulated under normoxia and hypoxia in TSP1 null pulmonary endothelial cells (Figure 5G). Cav-1 phosphorylation has been linked to eNOS activity. Treating hPAEC with TSP1 increased phosphorylation of Cav-1 at Tyr14, whereas pre-treating with a CD47-blocking antibody inhibited TSP1-mediated Cav-1 phosphorylation (Figure 5H).

### 3.8 CD47 is activated in a monocrotaline model of PAH

Monocrotaline-induced PAH is associated with dysregulated uncoupled eNOS, decreased Cav-1 expression, and increased pulmonary ROS production. In rats treated with monocrotaline pulmonary TSP1 and CD47 were upregulated (Figure 6A and B) and Cav-1 expression decreased (Figure 6E). Pulmonary eNOS activity was modestly decreased in monocrotaline-treated animals but was enhanced in animals treated with a rat-specific CD47-blocking antibody (Figure 6C).

### 3.9 Blocking CD47 activation suppresses pulmonary TSP1, upregulates Cav-1, and abrogates monocrotaline-induced PAH

Next, we tested if a CD47-blocking antibody could prevent monocrotaline-induced PAH. Animals received a CD47 antibody at the time of monocrotaline treatment and 14 days later. Control animals demonstrated increased RV systolic pressure and RV hypertrophy 4 weeks after monocrotaline treatment. In contrast, animals treated with a CD47 antibody demonstrated no significant elevation in RV systolic pressure or RV hypertrophy, as defined by Fulton Index (RV/LV+S), and minimal arteriole wall thickening in pulmonary tissue sections (Figure 6D). These protective effects were accompanied by both downregulation of pulmonary TSP1 (Figure 6A) and upregulation of pulmonary Cav-1 (Figure 6E).

### 4. Discussion

TSP1 has not previously been linked to clinical PAH. We now show that TSP1 protein and transcript are elevated in human PAH. Similarly, in two experimental models of PAH, we observed induction of pulmonary TSP1. CD47 was also upregulated in both clinical and experimental PAH and hypoxic pulmonary endothelial cells. TSP1 null pulmonary endothelial cells expressed significantly less CD47 compared with wild-type cells, and were resistant to hypoxic induction of CD47. These data suggest that TSP1 may also function to regulate CD47. Further, results herein identify CD47 as a proximate promoter of PAH. In the absence of CD47 activation, TSP1 null mice are protected from hypoxia-induced PAH. Compared with wild-type mice, TSP1 null animals displayed reduced RV systolic pressure and RV hypertrophy (by Fulton Index). Histological assessment of null lung sections showed fewer partial and fully muscularized pulmonary arterioles and less arteriole thickening. Also antibody blockade of CD47 activation in a rat model of PAH resulted in near-normal RV pressure and size, and minimal arteriole thickening.

Under hypoxic conditions, and in PAH, activated CD47 suppresses Cav-1 allowing uncoupled eNOS to produce pathological ROS. Conversely, hypoxic TSP1 null pulmonary endothelial cells and null mice, both lacking activated CD47, displayed significantly increased Cav-1 and decreased pathological ROS. That eNOS is the source of this pathological ROS is supported by the finding that ROS production was L-NAME inhibitable. Alternatively, suppression of Cav-1 has been linked to upregulation of NADPH-oxidase-dependent ROS suggesting an additional mechanism that, in part, may account for pathological ROS in our experiments. Though results in cell and animal studies demonstrate a clear link between CD47 activation and increased pulmonary ROS, it is not clear if this occurred concurrently with a decrease in bioavailable NO.

Post-translation control of eNOS occurs through a number of mechanisms including acetylation, calcium regulation, phosphorylation of key protein residues, and protein–protein interactions. Normoxic TSP1 null mice displayed increased activation of pulmonary eNOS (defined as increased serine phosphorylation). These
Figure 6 Blockade of CD47 activation upregulates Cav-1 and prevents experimental PAH. Age-matched male Sprague Dawley rats were treated with monocrotaline (mct, 50 mg/kg) ± a CD47-blocking antibody (clone OX101, 1 μg/gram body weight on day 1 and day 14 via i.p. injection). Animals were euthanized after 4 weeks. Lung lysates were prepared and proteins separated by SDS–PAGE electrophoresis. Blots were probed with a monoclonal antibody to (A) TSP1, (B) CD47, or (C) p-eNOS. Expression was quantified by densitometry and is presented as the mean ± SD. Densitometry results are from four animals in each group. (A) Asterisk (*) indicates statistically significant difference (P < 0.05) mct compared with control; Hash (#) indicates statistically significant difference (P < 0.05) mct compared with mct + CD47 antibody (Ab). (B) Asterisk (*) indicates statistically significant difference (P < 0.05) mct compared with control. (C) Asterisk (*) indicates statistically significant difference (P < 0.05) control compared with mct + CD47 antibody (Ab). (D) Age-matched male Sprague Dawley rats were treated with monocrotaline (mct) ± CD47 monoclonal antibody (Ab) (clone OX101, 1 μg/gram body weight) and right ventricular systolic pressure and RV/LV + S ratio (Fulton Index) measured at 4 weeks. Quantification of pulmonary arteriole wall thickness was performed by a blinded reviewer from tissue section images using an image analysis programme (Metamorph) with percent wall thickness defined as the wall thickness normalized to the vessel diameter and was specifically calculated by the following formula: wall thickness (%) = area external – area internal/area external × 100, where area external and area internal are the areas bounded by external elastic lamina and the lumen, respectively. Normalization was performed to account for increases in vessels size and wall thickness as a function of vessel diameter. Results are the mean ± SD of four animals in each group. Asterisk (*) indicates statistically significant difference (P < 0.05) mct compared with control. Hash (#) indicates statistically significant difference (P < 0.05) mct compared with mct + CD47 antibody (Ab). (E) Representative western blot of rat lung lysate from treated animals probed for Cav-1 and β-actin. Expression was quantified by densitometry presented as the mean ± SD from four animals in each group. Asterisk (*) indicates statistically significant difference (P < 0.05) control compared with mct. Hash (#) indicates statistically significant difference (P < 0.05) mct compared with mct + CD47 antibody (Ab).
results are consistent with our report that in normoxic endothelial cells activated CD47-inhibited eNOS through limiting cellular calcium, and inhibited NO-mediated stimulation of soluble guanylyl cyclase (sGC). It is possible that our current results in hypoxic null mice are, to some extent, mediated through these known functions of the TSP1-CD47 axis. This might also explain our finding that activated CD47 limited nitrite-mediated blood flow under hypoxic conditions. It remains to be determined if, under hypoxia, activated CD47 directly inhibits NO-mediated activation of sGC.

CD47 and Cav-1 constitutively co-associate on pulmonary endothelial cells. TSP1 and hypoxia, through TSP1 induction, activate CD47 to disrupt this co-association and free eNOS from the inhibitory and protective effects of Cav-1 in these situations. TSP1, via CD47, also increased Cav-1 phosphorylation in pulmonary endothelial cells. It is not clear how TSP1-mediated disruption of Cav-1CD47 co-association alters Cav-1 levels or how TSP1 alters Cav-1 phosphorylation. However, Cav-1 is a target of activated CD47, and hence downstream in this process, since knock-down of Cav-1 mitigates ROS suppression from a CD47-blocking antibody in hypoxic pulmonary arterial endothelial cells.

Taken together, these data demonstrate that TSP1-mediated activation of CD47 promotes superoxide production from uncoupled eNOS by limiting the expression and hence activity of Cav-1 (Figure 7). These studies are important, in that they describe for the first time a role for activated CD47 in both experimental PAH and human disease, and identify Cav-1 as a target of CD47 signalling.

**Funding**

This work was supported by the National Cancer Institute (K22 CA128616 to J.S.I.); the National Heart Lung and Blood Institute (R01 HL-108954 to J.S.I.); the National Institutes of Health TPPG PO1HL103455 to J.S.I.; the American Heart Association (11BGIA7210001 to J.S.I.); the Institute for Transfusion Medicine and the Hemophilia Center of Western Pennsylvania (to J.S.I.); the National Institutes of Health (R01 HL-085134 and TPPG PO1HL103455 to P.M.B.); and the Ministerio de Ciencia e Innovacion (SAF2009-11113 to M.F.C.).

**References**


**Supplementary material**

Supplementary material is available at Cardiovascular Research online.

**Conflict of interest:** J.S.I. is chair of the SAB of Vasculox, Inc. (St Louis, MO, USA) and Radiation Control Technologies, Inc. (Rockville, MD, USA).


